Plectasin Detection and Activity Assay Services

Comprehensive Plectasin Detection and Activity Assay Services for Quality Control, Fermentation Optimization, and Preclinical Development

Plectasin is a highly potent, defensin-type antimicrobial peptide originally derived from the saprophytic fungus Pseudoplectania nigrella. It exhibits strong bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae, through a unique mode of action involving inhibition of cell wall biosynthesis via lipid II binding. With its promising therapeutic potential, plectasin and its engineered variants are advancing toward preclinical and clinical applications, necessitating robust analytical methods for its precise quantification, purity assessment, and functional characterization across diverse matrices—from fermentation broths and purified protein samples to biological fluids and pharmaceutical formulations. However, plectasin analysis poses significant challenges: the small, cysteine-rich peptide is susceptible to oxidation and aggregation; it exhibits high sequence homology with other fungal defensins, requiring high-specificity detection; and its activity is highly dependent on proper disulfide bond formation, demanding bioassay-based functional testing alongside concentration measurements. Our specialized detection platform offers a fully integrated suite of physico-chemical, immunoassay, and cell-based functional assays tailored to plectasin, delivering the sensitivity, specificity, and reliability required for process development, quality assurance, regulatory submissions, and pharmacokinetic studies.

Scientific and Regulatory Drivers for Plectasin Analysis

Clients seeking plectasin detection services are motivated by a range of critical objectives. In fermentation and bioprocess development, the primary need is to monitor plectasin titers in real-time to optimize yields and harvest timing, while also tracking degradation products that may affect purity. In purification process validation, accurate quantification of plectasin across each step (e.g., capture, intermediate, polishing) is essential to calculate step yields and overall recovery. In quality control of drug substance and drug product, strict identity, content, and purity assays are required per ICH Q6B guidelines, including the detection of related substances (oxidized, aggregated, or truncated forms). In pharmacokinetic and toxicokinetic studies, sensitive and specific bioanalytical methods are needed to quantify plectasin concentrations in plasma, tissues, and excreta, with sufficient sensitivity to characterize its disposition and clearance. Furthermore, in antimicrobial susceptibility testing, determining the minimum inhibitory concentration (MIC) and the impact of matrix components on bioactivity is essential for evaluating clinical efficacy. Our service is designed to address these requirements, offering a modular analytical framework that can be adapted to the client's stage of development—from early discovery to GMP-compliant product release.

Integrated Analytical Pipeline for Comprehensive Plectasin Profiling

Our analytical platform comprises three interconnected modules that collectively deliver a complete characterization of plectasin quality, quantity, and functionality. The Quantitative and Purity Module employs reverse-phase ultra-high-performance liquid chromatography (RP-UHPLC) with photodiode array (PDA) detection at 280 nm and 220 nm, using a C18 column (1.7 µm) with a trifluoroacetic acid/acetonitrile gradient. This method resolves plectasin from its oxidized forms, deamidated variants, and other related impurities, achieving baseline resolution of the main peak from its principal degradation products and LOQ of 0.5 µg/mL with inter-day precision of ≤ 1.5% RSD. For higher sensitivity and absolute quantitation, we use liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a triple quadrupole mass spectrometer operating in selected reaction monitoring (SRM) mode, employing a stable isotope-labeled internal standard (e.g., plectasin-¹⁵N, or a labeled synthetic peptide) to correct for matrix effects. This achieves LOQs of 1 ng/mL in plasma and 0.1 ng/mL in buffer, with accuracy within 95–105% and linearity R² > 0.998 over a 4-log dynamic range. For identity confirmation, we use high-resolution mass spectrometry (HRMS) with intact mass measurement (mass error < 2 ppm) and MS/MS fragmentation matching to confirm the expected amino acid sequence and disulfide bonding pattern. The Purity and Impurity Module includes size-exclusion chromatography (SEC-HPLC) to quantify high-molecular-weight aggregates and low-molecular-weight fragments, with LOQ of 0.1% (area%) for aggregates and fragments, and capillary zone electrophoresis (CZE) for charge variant analysis (deamidation and oxidation profiles). Additionally, we perform forced degradation studies (thermal, photolytic, oxidative, and pH stress) to establish the intrinsic stability profile of the molecule and to validate the specificity of our purity methods. The Biological Activity Module uses a broth microdilution susceptibility assay against a panel of reference strains (e.g., S. aureus ATCC 29213, MRSA ATCC 33591) according to CLSI guidelines, reporting the minimum inhibitory concentration (MIC) with 95% confidence intervals. For high-throughput activity screening, we also employ a bioluminescence-based ATP depletion assay (using a susceptible indicator strain), which provides potency data within 4 hours with inter-assay variability < 10%. Furthermore, we offer a lipid II binding competition assay using surface plasmon resonance (SPR) or biolayer interferometry (BLI) to directly measure the affinity of plectasin to its target, providing a biophysical confirmation of functional integrity independent of whole-cell assays.

Unmatched Analytical Sensitivity, Specificity, and Structural Resolution

Our platform consistently delivers performance metrics that exceed typical industry standards. In LC-MS/MS, our optimized sample preparation (solid-phase extraction with mixed-mode sorbents) yields matrix effect values < 10% for plasma and extraction recoveries > 92%. The SRM method monitors multiple characteristic transitions for plectasin (e.g., doubly and triply charged precursor ions to specific fragment ions) to ensure specificity against endogenous interfering substances, with a signal-to-noise ratio > 100:1 at the LOQ. In RP-UHPLC, our method achieves peak symmetry (As ≤ 1.2) and theoretical plate counts > 20,000 per column, ensuring reliable quantification even in complex matrices. For impurity profiling, our SEC method resolves dimer and larger aggregates with retention time precision < 0.1% RSD, and our CZE method separates charge variants with baseline resolution of deamidated species. In bioactivity assays, we use highly characterized reference standard (traceable to a primary standard) to calibrate each run, and we provide relative potency values (as % of reference) with validated acceptance criteria (e.g., 80–120%) per USP^∗ <1032>. Additionally, we have developed a proprietary ELISA (sandwich-type, using monoclonal antibodies raised against a conformational epitope) that provides a LOQ of 0.1 ng/mL in buffer and 1 ng/mL in serum, offering a rapid, high-throughput option for large-scale screening. The antibodies have been validated for cross-reactivity against oxidized plectasin and the linear peptide to ensure that the assay specifically measures the native, bioactive form. Our multi-tiered approach ensures that clients receive not only a single concentration value but a comprehensive profile of molecular integrity and biological function.

Distinctive Advantages of Our Plectasin Detection Service

Our service offers several unique benefits that provide exceptional value to our clients. First, we have developed matrix-specific validation packages for a wide range of sample types—including fermentation broths, cell lysates, purified protein solutions, human and animal plasma, urine, and tissue homogenates—each with optimized extraction, cleanup, and chromatographic conditions that have been rigorously tested for linearity, accuracy, precision, and stability. Second, we maintain a comprehensive reference standard library that includes the native plectasin, its oxidized and deamidated forms, and several engineered variants (e.g., the drug candidate NZ2114 and its derivatives), enabling rapid identification of unknown peaks in impurity profiles. Third, we provide a rapid screening service using a MALDI-TOF mass spectrometry workflow that delivers qualitative confirmation of plectasin identity and approximate purity within 2 hours of sample receipt, ideal for in-process checks or troubleshooting. Fourth, our integrated stability assessment includes not only chemical stability but also biological activity retention under accelerated and real-time storage conditions, providing clients with shelf-life predictions and critical data for formulation development. Fifth, we offer customized method development and validation services to meet specific client requirements, such as extremely low LOQs for sensitive PK studies or high-throughput automation for QC release. Sixth, all our analytical methods are compliant with ICH Q2(R1), ICH Q6B, and USP guidelines for biological product characterization, and we provide full validation documentation including specificity, linearity, precision, accuracy, range, LOD, LOQ, robustness, and system suitability, making our data ready for regulatory submission. Our team of peptide chemistry and bioassay experts also provides dedicated interpretive support, helping clients to understand subtle changes in chromatographic profiles or potency shifts that may indicate process or product issues.

Advanced Data Interpretation, Modeling, and Regulatory-Ready Reporting

We understand that the value of analytical data is fully realized only when it informs decision-making. Our reports are structured to deliver three levels of insight: (i) a certificate of analysis (CoA) summarizing the key quality attributes (content, purity, potency, identity) against client-defined specifications, with clear pass/fail indicators; (ii) a comprehensive analytical report containing all raw chromatograms, mass spectra, bioassay plates, and QC data, along with a detailed method description and system suitability results; and (iii) an interpretive summary written in accessible scientific language, discussing any deviations from expectations and suggesting potential root causes or corrective actions. For stability studies, we provide regression analysis and shelf-life projections using ICH Q1E methodology, calculating the time at which the 95% lower confidence interval intersects the acceptance limit. For process optimization clients, we perform multivariate trend analysis (e.g., PCA) across multiple batches to identify critical process parameters that influence product quality. We also provide raw data files in open formats (e.g., .mzML for MS, .dx for chromatography) for clients who wish to conduct their own in-depth bioinformatics. Our reporting is aligned with the requirements of global regulatory agencies, and we can tailor the format to suit specific submission dossiers (e.g., IMPD, IND, BLA).

Broad Applications Across Fermentation, Purification, Formulation, and Clinical Research

The versatility of our plectasin detection service spans the entire product lifecycle. In fermentation development, our rapid titer monitoring enables precise control of induction and harvest timing, maximizing productivity. In purification process development, our high-resolution HPLC and LC-MS methods track the removal of impurities and the recovery of the active species across each chromatography step. In formulation development, our stability and bioactivity assays guide the selection of excipients, pH, and buffer systems to minimise degradation and maintain potency. In quality control of bulk drug substance and finished product, our validated release assays ensure that every batch meets the specifications for identity, purity, content, and activity. In preclinical and clinical studies, our sensitive bioanalytical methods enable pharmacokinetic profiling, bioavailability assessments, and toxicokinetic evaluation, providing essential data for dose selection and safety evaluation. In comparative product studies, we provide head-to-head analytical comparison of innovator and biosimilar/follow-on versions of plectasin-based products. We also support academic research by providing detailed molecular characterization of novel plectasin mutants or production strains. Our ability to adapt methods to the client's specific needs has made us a trusted partner for both small biotech firms and large pharmaceutical companies.

Commitment to Innovation, Quality, and Client Partnership

We are dedicated to maintaining leadership in peptide analytics through continuous technological investment and method innovation. Our current R&D includes the development of immunoassay-based lateral flow devices for rapid on-site testing of plectasin titer during fermentation, and the implementation of two-dimensional liquid chromatography (2D-LC) for enhanced separation of complex impurity profiles. We actively participate in international collaborative studies to harmonize methods for antimicrobial peptide analysis, and we contribute to the development of reference standards. Our quality management system is ISO 9001 and ISO/IEC 17025 accredited, and our biological safety testing follows GLP principles. We offer flexible service models, from single-sample analysis to long-term contracts with dedicated capacity, volume discounts, and priority processing. Our global logistics network ensures the safe and compliant shipment of biological samples (e.g., human plasma, fermentation broths) under the required temperature conditions, with detailed sampling and shipping instructions. Turnaround times are typically 3–5 business days for standard analytical panels and 24–48 hours for emergency assessments. We maintain open and transparent communication throughout the project, providing regular updates and rapid responses to client inquiries. Ultimately, our commitment is to deliver not only accurate results but also the scientific confidence that empowers our clients to advance their plectasin-based products with safety and efficacy. We invite you to collaborate with us for rigorous, reliable, and insightful analytical support for your plectasin projects.

In summary, our plectasin detection service offers a comprehensive, precise, and regulatory-ready analytical solution that integrates high-resolution chromatography, high-sensitivity mass spectrometry, and robust bioactivity assays. By tailoring methods to the specific matrix and application, providing deep interpretive insights, and adhering to the highest quality standards, we enable our clients to achieve consistent product quality, optimize production processes, and accelerate their development timelines. We look forward to supporting your plectasin analyses with our dedicated expertise and advanced capabilities.